title: "Triple therapy" or triple threat? Balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents.
authors.forename: Steven
authors.initials: S
authors.lastname: Francescone
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Halperin
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D001241:Aspirin / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use*; D012307:Risk Factors; D015607:Stents / Q000009:adverse effects; D013923:Thromboembolism / Q000209:etiology* / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D011725:Pyridines; C446540:thienopyridine; D014859:Warfarin; D001241:Aspirin